Teleflex (NYSE:TFX) Price Target Raised to $170.00

Teleflex (NYSE:TFX) had its target price lifted by Needham & Company LLC from $159.00 to $170.00 in a report published on Tuesday morning, MarketBeat.com reports. Needham & Company LLC currently has a buy rating on the medical technology company’s stock.

Several other research firms have also recently weighed in on TFX. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research report on Wednesday, June 24th. Truist Financial upped their target price on shares of Teleflex from $143.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. BMO Capital Markets initiated coverage on Teleflex in a research note on Wednesday, July 8th. They set an “outperform” rating and a $159.00 price target for the company. Wall Street Zen raised Teleflex from a “sell” rating to a “hold” rating in a research note on Sunday, August 9th. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $150.00 price objective on shares of Teleflex in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Teleflex has a consensus rating of “Hold” and a consensus price target of $152.90.

Teleflex Stock Down 0.8%

TFX stock opened at $137.65 on Tuesday. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. The company’s 50 day moving average is $133.60 and its 200 day moving average is $125.81. The stock has a market cap of $5.83 billion, a price-to-earnings ratio of -5.91, a price-to-earnings-growth ratio of 0.92 and a beta of 0.81. Teleflex has a 1-year low of $100.18 and a 1-year high of $145.00.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The business had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. During the same period last year, the firm posted $3.73 earnings per share. Teleflex’s quarterly revenue was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Sell-side analysts predict that Teleflex will post 7.26 EPS for the current fiscal year.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Friday, August 14th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Friday, August 14th. Teleflex’s dividend payout ratio (DPR) is presently -5.84%.

Institutional Trading of Teleflex

Several hedge funds have recently added to or reduced their stakes in TFX. Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Teleflex by 227.5% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 27,822 shares of the medical technology company’s stock worth $3,395,000 after purchasing an additional 19,327 shares during the period. First Eagle Investment Management LLC boosted its stake in shares of Teleflex by 163.4% during the fourth quarter. First Eagle Investment Management LLC now owns 84,300 shares of the medical technology company’s stock valued at $10,288,000 after purchasing an additional 52,300 shares during the period. Baader Bank Aktiengesellschaft boosted its stake in shares of Teleflex by 32.4% during the fourth quarter. Baader Bank Aktiengesellschaft now owns 43,333 shares of the medical technology company’s stock valued at $5,288,000 after purchasing an additional 10,600 shares during the period. Diamond Hill Capital Management Inc. grew its holdings in shares of Teleflex by 6.3% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 349,809 shares of the medical technology company’s stock worth $42,691,000 after purchasing an additional 20,773 shares during the last quarter. Finally, Fifth Third Bancorp grew its holdings in shares of Teleflex by 3,204.8% in the first quarter. Fifth Third Bancorp now owns 68,144 shares of the medical technology company’s stock worth $8,151,000 after purchasing an additional 66,082 shares during the last quarter. 95.62% of the stock is owned by institutional investors.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.